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The antigenic targets recognized by naturally occurring CD4
 
  
 
CD25
 
  
 
regulatory T cells (T reg 
cells) have been elusive. We have serologically defined a series of broadly expressed self-
antigens derived from chemically induced mouse sarcomas by serological identification of 
antigens by recombinant expression cloning (SEREX). CD4
 
  
 
CD25
 
  
 
T cells from mice 
immunized with SEREX-defined self-antigens had strong suppressive activity on peptide-
specific proliferation of CD4
 
  
 
CD25
 
  
 
T cells and CD8
 
  
 
T cells. The suppressive effect was 
observed without in vitro T cell stimulation. 
 
Foxp3
 
 expression in these CD4
 
  
 
CD25
 
  
 
T cells 
from immunized mice was 5–10 times greater than CD4
 
  
 
CD25
 
  
 
T cells derived from naive 
mice. The suppressive effect required cellular contact and was blocked by anti-glucocorticoid–
induced tumor necrosis factor receptor family–related gene antibody. In vitro suppressive 
activity essentially disappeared 8 wk after the last immunization. However, it was regained 
by in vitro restimulation with cognate self-antigen protein but not with control protein. 
We propose that SEREX-defined self-antigens such as those used in this study represent 
self-antigens that elicit naturally occurring CD4
 
 
 
 CD25
 
 
 
 T reg cells.
 
Evidence for the essential role of regulatory
T cells (T reg cells) in maintaining immuno-
logical homeostasis comes from a range of in
vitro and in vivo experimental systems, and
naturally occurring T reg cells coexpressing
CD4 and CD25 are of central interest with
regard to the regulation of autoreactive T cells
(1–3). Although the expression of CD25 (IL-2R
 
  
 
chain) is not restricted to naturally occurring
T reg cells, IL-2 signaling appears to be essen-
tial for their generation in the thymus, their
peripheral maintenance, and their suppressive
function (4–6). Glucocorticoid-induced TNF
receptor family–related gene (GITR) may
possess more direct functional relevance with
regard to naturally occurring T reg cells as in-
dicated by evidence that anti-GITR antibody
blocks the suppressive activity of T reg cells
(7, 8). However, it has been shown that the
reversal of suppression by anti-GITR antibody
is attributable to the costimulatory activity of
anti-GITR antibody on the responder CD4
 
 
 
CD25
 
  
 
T cells (9), and therefore, the cellular
target of anti-GITR antibody for blocking
suppression needs to be reevaluated. Recently,
the forkhead/winged helix transcription factor
 
Foxp3
 
 has been shown to be essential in direct-
ing T cells toward a suppressor phenotype, and
for this reason, 
 
Foxp3
 
 has become a key marker
for naturally occurring T reg cells (10–12).
Naturally occurring T reg cells are thought
to be maintained through interaction with self-
antigens. However, despite the many indications
that self-antigens play a critical role in the devel-
opment of T reg cells (13–16), a limited number
of self-antigen ligands of naturally occurring
T reg cells have been identified (17). For this
reason, molecular definition of these natural
ligands is a top priority in the T reg cell field.
We have recently reported that immuniza-
tion with serological identification of antigens
by recombinant expression cloning (SEREX)-
defined self-antigens results in enhancement
of pulmonary metastasis of i.v.-challenged
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immunogenic transplantable tumor lines (18). These self-
antigens were identified by SEREX, a methodology widely
used to identify immunogenic molecules in mouse and
human tumors (19–21).
In this analysis, we have found that CD4
 
  
 
CD25
 
  
 
T cells
obtained from mice immunized with SEREX-defined self-
antigens display strong suppressive effect on IL-2 production
and proliferation of CD4
 
  
 
CD25
 
  
 
T cells, and this effect
depends on cellular contact and is independent of soluble
mediators. Although these T reg cells closely resemble the
widely studied naturally occurring CD4
 
  
 
CD25
 
  
 
T reg cells
found in naive hosts, they have stronger immunosuppressive
activity and do not require in vitro stimulation with anti-
CD3 mAb. In addition, the CD4
 
  
 
CD25
 
  
 
T cells elicited by
immunization with SEREX-defined self-antigens display
significantly enhanced levels of 
 
Foxp3
 
 mRNA expression.
 
RESULTS AND DISCUSSION
Immunization with SEREX-defined self-antigens elicits 
active CD4
 
  
 
CD25
 
  
 
T reg cells
 
BALB/c mice were immunized twice at 2-wk intervals by
gene gun with plasmids encoding the following SEREX-
defined self-antigens: Mus heat shock protein Dna J–like 2
(Dna J–like 2; AF055664), Mus DNA ligase 1 (Ligase 1;
U19604), Mus galectin-8 (Galectin-8; AF218069), or Mus
poly (A) binding protein, cytoplasmic 1 (Poly (A); X65553).
1 wk after immunization, splenic CD4
 
  
 
CD25
 
  
 
T cells and
CD4
 
  
 
CD25
 
  
 
T cells were isolated using microbeads (see
Materials and methods) and added to cultures of naive
CD4
 
  
 
CD25
 
  
 
T cells from DO11.10 mice or naive CD8
 
 
 
T cells from DUC18 mice stimulated with APC and cognate
antigenic peptides. CD4
 
  
 
CD25
 
  
 
T cells from mice immu-
nized with SEREX-defined self-antigens showed significant
suppression of the peptide-specific proliferation of CD4
 
 
 
CD25
 
  
 
T cells and CD8
 
  
 
T cells, whereas CD4
 
  
 
CD25
 
 
 
T cells from naive BALB/c mice or mice immunized with
plasmids encoding the following SEREX-unrelated mole-
cules (nonimmunogenic molecules randomly picked from
the SEREX screening library) showed essentially no sup-
pression: Mus glucose–regulated protein (Glucose-regulated;
D78645), Mus sorting nexin 1 (Sorting nexin; AB019214),
or Mus Cctz-1 gene for chaperon-containing TCP-1-
 
 
 
-1
subunit (Cctz-1; AB022159), or with control vector (Fig. 1 a).
Furthermore, no proliferative suppression of CD4
 
  
 
CD25
 
 
Figure 1. Immunization with SEREX-defined self-antigens elicits 
active CD4  CD25  T reg cells. (a) BALB/c mice were immunized with 
plasmids encoding SEREX-defined self-antigens, SEREX-unrelated mole-
cules, heterologous molecules, or control vector. 1 wk after the second 
immunization, 5   104 CD4  CD25  T cells or 5   104 CD4  CD25  T cells 
from spleens were added to cultures of 5   104 CD4  CD25  T cells from 
DO11.10 mice or 5   104 CD8  T cells from DUC18 mice with 5   104 
MMC-treated BALB/c splenic Thy-1  APC and cognate peptides. (b) 5   104 
CD4  CD25  T cells from DO11.10 mice were cultured with 5   104 MMC-
treated BALB/c splenic Thy-1  APC and cognate peptides in the presence 
of FACSVantage-sorted 5   104 CD4  CD25  or CD4  CD25  T cells from 
naive or Dna J–like 2–immunized BALB/c mice. (c) 5   104 CD8  T cells 
from DUC18 mice were cultured with 5   104 CD4  CD25  T cells from 
naive or Dna J–like 2–immunized BALB/c mice with 5   104 MMC-treated 
BALB/c splenic Thy-1  APC and cognate peptides with or without anti–MHC 
class II mAb. Proliferation was assessed as described in Materials and 
methods. These experiments were repeated three (a) or two (c) times with 
similar results. Data are expressed as mean   SD. 
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T cells or CD8
 
  
 
T cells was observed with CD4
 
  
 
CD25
 
  
 
T
cells from mice immunized with the following plasmids en-
coding heterologous human antigens (21): 
 
Homo sapiens
 
HMBA-inducible (HMBA-inducible; XM_008348), hu-
man retinoic acid–responsive protein (Retinoic acid–respon-
sive; U50383), or OVA. However, CD4
 
  
 
CD25
 
  
 
T cells
from all groups suppressed the proliferation of CD4
 
 
 
CD25
 
  
 
T cells and CD8
 
  
 
T cells when anti-CD3 mAb was
added to the cultures, in accordance with previous reports
(2, 3, 22). To exclude the possibility that multivalent cross-
linking by antibodies conjugated to microbeads during
CD4
 
  
 
CD25
 
  
 
T cell purification alters their function, the
cells were purified on a FACSVantage from negatively se-
lected CD4
 
  
 
T cells. Consistent with previous experiments,
CD4
 
  
 
CD25
 
  
 
T cells purified on a FACSVantage from
mice immunized with Dna J–like 2 (one of the SEREX-
defined self-antigens) showed similar suppressive capacity (Fig.
1 b). Suppression of CD4
 
  
 
CD25  T cell and CD8  T cell
proliferation by CD4  CD25  T cells derived from mice
immunized with Dna J–like 2 was contact dependent, cy-
tokine independent, blocked by anti-GITR, and associated
with suppression of IL-2 production by responder T cells
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20041959/DC1). Finally, CD4  CD25  T cells derived
from mice immunized with Dna J–like 2 had a suppressive
effect on CD8  T cell proliferation even in the presence of
anti–MHC class II mAb, indicating “no necessity” for in
vitro stimulation of CD4  CD25  T cells by self-antigens in
the context of MHC class II (Fig. 1 c). Thus, this set of ex-
periments shows that immunization with SEREX-defined
self-antigens elicits CD4  CD25  T cells with extremely
potent regulatory activity.
High Foxp3 mRNA expression is found in CD4  CD25  T cells 
from mice immunized with SEREX-defined self-antigens
Foxp3 mRNA expression in CD4  T cell subsets was ex-
amined 1 wk after immunization with SEREX-defined
self-antigens (Fig. 2). Enhanced expression of Foxp3
Figure 2. Expression of Foxp3 mRNA is enhanced in CD4  CD25  T 
cells from mice immunized with SEREX-defined self-antigens. BALB/c 
mice were immunized with plasmids encoding SEREX-defined self-antigens, 
SEREX-unrelated molecules, heterologous molecules, or control vector. 
1 wk after the second immunization, CD4  CD25  T cells and CD4  CD25  
T cells were purified from spleens and their levels of Foxp3 mRNA were 
assessed by real-time quantitative RT-PCR. Normalized Foxp3 mRNA 
expression values were calculated as the ratio of Foxp3 mRNA expression 
to HPRT mRNA expression. These experiments were repeated three times 
with similar results. Data are expressed as mean   SD.
Figure 3. Changes in CD4  CD25  T cell suppressive activity after 
immunization are correlated with Foxp3 mRNA expression levels. 
(a) 1, 4, or 8 wk after the second immunization with plasmids encoding 
Dna J–like 2, CD4  CD25  T cells were obtained from spleens. Graded 
doses of these cells were added to cultures of 5   104 CD4  CD25  T cells 
from DO11.10 mice or 5   104 CD8  T cells from DUC18 mice with 5   104 
MMC-treated BALB/c splenic Thy-1  APC and cognate peptides. Prolifera-
tion was assessed as described in Materials and methods. (b) cDNA was 
prepared from CD4  CD25  T cells at various time intervals after immuni-
zation with Dna J–like 2. The expression of Foxp3 mRNA was analyzed as 
described in the legend of Fig. 2. These experiments were repeated three 
times with similar results. Data are expressed as mean   SD.SELF-ANTIGENS RECOGNIZED BY CD4  CD25  T CELLS | Nishikawa et al. 684
mRNA was observed in CD4  CD25  T cells from mice
immunized with each of the four different SEREX-defined
self-antigens. Expression levels were 5–10 times higher
than those found in CD4  CD25  T cells from naive mice,
mice immunized with the control vector, mice immunized
with SEREX-unrelated molecules, or heterologous mole-
cules. Levels of Foxp3 mRNA expression in CD4  CD25 
T cells from all groups of mice remained unchanged after
immunization.
We then examined the suppressive capacity and levels of
Foxp3 mRNA expression in CD4  CD25  T cells from
mice immunized with SEREX-defined self-antigens at vari-
ous time intervals after immunization. Suppressive activity
was strongest when CD4  CD25  T cells were obtained 1
wk after immunization, becoming marginal when the cells
were obtained 8 wk after immunization (Fig. 3 a). In parallel
to the decrease in suppressive activity of CD4  CD25  T
cells, Foxp3 mRNA expression was also highest when CD4 
CD25  T cells were obtained 1 wk after immunization and
decreased thereafter (Fig. 3 b).
Antigen-specific stimulation restores suppressive activity of 
CD4  CD25  T cells from Dna J–like 2 immunized mice
As the suppressive activity of CD4  CD25  T cells declines
after immunization, we asked whether self-antigens used for
in vivo immunization could restimulate CD4  CD25  T cells
in vitro. CD4  CD25  T cells obtained 8 wk after immuni-
zation with Dna J–like 2 lost suppressive activity (Fig. 4 a).
However, they became strongly suppressive when rDna
J–like 2 protein, but not control rHER2 protein, was added to
the cultures. The regained suppressive capacity of in vitro–
stimulated CD4  CD25  T cells was also contact dependent
and cytokine independent (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20041959/DC1). The
presence of anti–MHC class II mAb abrogated the reactiva-
tion of the suppressive effect of these CD4  CD25  T cells
by rDna J–like 2 protein (Fig. 4 b). Anti–MHC class II mAb
did not interfere with the suppressive activity of CD4 
CD25  T cells from naive or Dna J–like 2–immunized mice
induced by anti-CD3 mAb.
Our studies have shown that immunization with
SEREX-defined self-antigens generates CD4  CD25  T cells
that exert potent suppressive activity and express elevated lev-
els of Foxp3 mRNA expression. The characteristic of these
CD4  CD25  T cells clearly resembles naturally occurring T
reg cells. It is unclear at present whether increased suppressive
activity and elevated Foxp3 mRNA expression are due to the
clonal expansion of SEREX-defined self-antigen–specific
CD4  CD25  T cells or to the increase of activity per cell.
Although recent reports have demonstrated that CD4 
CD25  T cells proliferate in vivo in an antigen-specific fash-
ion like CD4  CD25  T cells (23–25), we could not detect
any increase in the percentage of CD4  CD25  T cells in
spleen, lymph node, and pulmonary cells from mice immu-
nized with Dna J–like 2 (18). These data are in line with the
report that tolerization to dnaJP1 by mucosal immunization
increases Foxp3 expression in CD4  CD25bright T cells with-
out an obvious increase in the total number of dnaJP1-spe-
cific T cells (26). Nevertheless, it is still possible that SEREX-
defined self-antigen–specific CD4  CD25  T cells clonally
expand, but this expansion is under the detection level of
flow cytometric analysis. It is also possible that expression of
Figure 4. Antigen-specific stimulation restores suppressive activity 
of CD4  CD25  T cells from Dna J–like 2–immunized mice. (a) 1 or 8 
wk after the second immunization with plasmids encoding Dna J–like 2, 
5   104 CD4  CD25  T cells were obtained from spleens. The suppressive 
activity was analyzed as described in the legend of Fig. 1 a. (b) 5   104 
CD8  T cells from DUC18 mice were cultured with 5   104 CD4  CD25  
T cells from mice 8 wk after the second immunization with 5   104 MMC-
treated BALB/c splenic Thy-1  APC and cognate peptides, with or without 
anti–MHC class II mAb, and with or without in vitro stimulation as indicated. 
Proliferation was assessed as described in Materials and methods. These 
experiments were repeated three (a) or two (b) times with similar results. 
Data are expressed as mean   SD.JEM VOL. 201, March 7, 2005 685
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Foxp3 mRNA could be increased on a per cell basis after
stimulation with SEREX-defined self-antigens in vivo.
A unique finding in our analysis is that although SEREX-
defined self-antigens, but not heterologous antigens, elicit
CD4  CD25  T reg cells with potent suppressive activity,
both antigens can induce equivalent CD4  T cell–dependent
helper T cell activity for enhancing tumor-specific CTLs
(21). The reason for this difference is currently unknown.
Although several recent reports have described the presence
of CD4  T cells for heterologous antigens with suppressive
activity (27, 28), constant stimulation with self-antigens, rep-
resented by SEREX-defined self-antigens, may create a fa-
vorable environment for activation of self-antigen–specific
CD4  CD25  T reg cells that maintain immunological ho-
meostasis. Immunization with SEREX-defined self-antigens
under the condition of our study appears to favor prompt
elicitation or recall of these CD4  CD25  T reg cells.
Although SEREX was introduced to identify tumor anti-
gens that elicited a humoral immune response in the tumor-
bearing host, the vast majority of these antigens were not
restricted to tumors but were broadly expressed, nonmutated
self-antigens (19–21). Thus, SEREX has the potential of
defining  the repertoire of immunogenic self-antigens. As
these immunogenic molecules are detected by IgG class anti-
bodies, SEREX also represents a powerful indirect way to
study the CD4  T cell repertoire. Our analysis indicates that a
number of these immunogenic wild-type molecules detected
by SEREX are recognized by CD4  CD25  T reg cells and
elicit CD4  CD25  T reg cells with suppressive activity. As
coimmunization with SEREX-defined self-antigens and a
CTL epitope enhances CD8  CTL induction in a CD4 
T cell–dependent manner (21), these self-antigens are also
likely to be recognized by CD4  helper T cells. Two possi-
bilities to explain these findings regarding the relation be-
tween SEREX-defined self-antigens and helper and T reg
cells are that CD4  T cells with different functions yet recog-
nizing the same self-antigens exist in the periphery, or that
single CD4  precursors gain distinct functions under different
circumstances of antigenic stimulation. We have recently
found that IFN- , but not several other cytokines, produced
by CD8  CTLs recognizing CTL epitopes used for coimmu-
nization with SEREX-defined self-antigens suppresses gener-
ation of CD4  CD25  T reg cells recognizing SEREX-
defined self-antigens (unpublished data). This ability of
IFN-  to nullify suppression provides an explanation for the
paradoxical effect of immunization with self-antigens and
CTL epitopes, where strong helper activity is generated in
contrast to the suppression seen when mice are immunized
with self-antigens alone. Our interpretation of these findings
is that IFN-  produced by CD8  T cells responding to a CTL
epitope inhibits generation of CD4  CD25  T reg cells, per-
mitting CD4  CD25  helper T cells to become dominant.
The role of SEREX-defined self-antigens in generating and
maintaining CD4  CD25  T reg cells and CD4  helper T cells
is clearly a critical area for future exploration. An important
next step will be to define the peptide sequences in these self-
antigens that elicit diverse CD4  T cell responses.
MATERIALS AND METHODS
Mice. Female BALB/c mice and C.B-17 SCID mice were purchased from
CLEA Japan and used at 7–10 wk of age. DUC18 mice, transgenic for   
TCR reactive with the Kd-restricted mERK2136–144, were established as de-
scribed previously (29). DO11.10 mice, transgenic for    TCR reactive
with the I-Ad–restricted OVA323–339 (30), were provided by K.M. Murphy
(Washington University, St. Louis, MO). Mice were maintained at the
Animal Center of Mie University School of Medicine. The experimental
protocol was approved by the Ethics Review Committee for Animal Ex-
perimentation of Mie University School of Medicine.
Immunization by gene gun. Gold particles coated with plasmid DNA
(1  g/injection) were prepared and delivered into shaved skin of the ab-
dominal wall of BALB/c mice by a Helios Gene Gun System (Bio-Rad
Laboratories) at a helium discharge pressure of 350–400 psi, as described
previously (21).
Antibodies and reagents. Anti-CD3 mAb (145-2C11; hamster IgG) and
anti–I-Ad mAb (M5/114; rat IgG2b) were purified from ascites of each hybrid-
oma in C.B-17 SCID mice on a protein A column. FITC-conjugated anti-
CD25 antibody (PC61; rat IgG1) was purchased from eBioscience. PE-conju-
gated anti-CD4 (H129.19; rat IgG2a) was purchased from BD Biosciences.
Synthetic mERK2136–144-9m peptide QYIHSANVL (21) and OVA323–339
peptide ISQAVHAAHAEINEAGR (30) were obtained from TAKARA
SHUZO. cDNA encoding SEREX-defined molecules, control SEREX-unre-
lated molecules, and heterologous molecules were cloned into pBK-CMV
(Stratagene) and purified using the EndoFree Plasmid Mega Kit (QIAGEN).
Purification of CD4  CD25  T cells and CD4  CD25  T cells.
Spleen cells were fractionated into CD25  and CD25  using MACS Anti-
FITC MultiSort Kit (Miltenyi Biotec). Anti-FITC microbeads bound to
CD25  cells were detached using MACS MultiSort Release Reagent and
MACS MultiSort Stop Reagent according to the manufacturer’s instruc-
tions. The resultant CD25  and CD25  cells were further enriched for
CD4  cells by positive selection on a MACS column after reacting with
anti-CD4 microbeads. CD4  CD25  and CD4  CD25  T cell preparations
were confirmed to contain  96 and  93%, respectively. CD4  T cells
were enriched by negative selection using a CD4  isolation kit (Miltenyi
Biotec) followed by purification of CD4  CD25  and CD4  CD25  T cells
on a FACSVantage (BD Biosciences) after staining with FITC–anti-CD25
and PE–anti-CD4. The purity of these CD4  CD25  and CD4  CD25 
T cells was  99%.
Proliferation assay. 5   104 CD4  CD25  T cells from DO11.10 mice or
5   104 CD8  T cells from DUC18 mice were cultured with 5   104 mito-
mycin C (MMC)-treated splenic Thy-1  APCs from wild-type BALB/c
mice in the presence of 10  g/ml OVA323–339 peptide or mERK2136–144-9m
peptide in the wells of 96-well flat-bottomed plates. To these cultures, CD4 
CD25  or CD4  CD25  T cells were added. Proliferation was evaluated by
pulsing with 0.5  Ci/well [3H]thymidine for the last 6 h of the 72-h culture.
Real-time quantitative RT-PCR. Oligo-dT–primed first strand cDNA
of Foxp3 or HPRT was synthesized for real-time RT-PCR. Real-time
RT-PCR was performed as described previously (10).
Online supplemental material. Fig. S1 shows that the suppressive effect
of active CD4  CD25  T reg cells was dependent on cellular contact and
blocked by GITR antibody. Fig. S2 shows that the regained suppressive
capacity of in vitro–stimulated CD4  CD25  T cells was also contact
dependent and cytokine independent. Figs. S1 and S2 are available at
http://www.jem.org/cgi/content/full/jem.20041959/DC1.SELF-ANTIGENS RECOGNIZED BY CD4  CD25  T CELLS | Nishikawa et al. 686
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